1-苄基-6-羟基-3-甲基吲唑 | 519158-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1-苄基-6-羟基-3-甲基吲唑
• 英文名称: 1-benzyl-3-methyl-1H-indazol-6-ol
• 英文别名: 1-benzyl-6-hydroxy-3-methylindazole；1-Benzyl-3-methylindazol-6-ol
• CAS: 519158-44-2
• 化学式: C₁₅H₁₄N₂O
• 分子量: 238.289
• InChiKey: NPPRJCSNCCQTIK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-苄基-6-羟基-3-甲基吲唑 在 4-二甲氨基吡啶 、 5%-palladium/activated carbon 、 palladium 10% on activated carbon 咪唑 、 盐酸 、 偶氮二甲酰胺 、 四丁基氟化铵 、 氢气 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 tert-butyl 6-(2-(benzylamino)ethoxy)-3-methylindazole-1-carboxylate
  参考文献：
  名称：

  EP2484668

  摘要：

  公开号：
• 作为产物：
  描述：

  1-benzyl-3-methyl-6-methoxyindazole 在 吡啶盐酸盐 、 sodium hydroxide 作用下， 以 H₂₀ 为溶剂， 反应 2.5h， 生成 1-苄基-6-羟基-3-甲基吲唑
  参考文献：
  名称：

  BICYCLIC COMPOUND

  摘要：

  公开号：

  EP1447400B1

文献信息

• INDAZOLE COMPOUNDS
  申请人：Nakano Seiji

  公开号：US20100160256A1

  公开（公告）日：2010-06-24

  Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

  提供的是以下公式（A-1）和公式（1）所代表的化合物，或其盐。公式（A-1）和公式（1）的化合物或其盐具有133肾上腺素受体激动剂活性，因此可作为治疗和预防糖尿病、肥胖、高脂血症、抑郁症、胆石症或胆道高动力性疾病、消化系统过度活动引起的疾病、间质性膀胱炎、膀胱过度活动或尿失禁的药物，或作为治疗和预防伴随眼泪减少的疾病的药物。
• Bicyclic compound
  申请人：Miyoshi Shiro

  公开号：US20050020602A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R 2 represents NHSO 2 R 3 , etc., provided that R 3 represents C 1-6 alkyl, etc. R 5 represents hydrogen, etc. R 6 and R 7 may be the same or different and each independently represents hydrogen, etc. X represents oxygen, etc. Y represents oxygen, etc. Z 1 to Z 6 each represents carbon, etc. n is an integer of 0 to 6 and ast1 indicates that the carbon atom is asymmetric, and *2, in the case where R 5 is not hydrogen, indicates that the carbon atom is asymmetric or a salt of the compound.

  化合物的通式为I：I，其中R1代表氢等，R2代表NHSO2R3等，但R3代表C1-6烷基等，R5代表氢等，R6和R7可以相同也可以不同，且各自独立地代表氢等，X代表氧等，Y代表氧等，Z1至Z6各自代表碳等，n为0至6的整数，ast1表示碳原子是不对称的，*2表示当R5不是氢时，碳原子是不对称的或化合物的盐。
• Indole compounds as B3 androceptor agonist
  申请人：Miyoshi Shiro

  公开号：US20080076815A1

  公开（公告）日：2008-03-27

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式(I)的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是(C1-C6)烷基或类似物；R5是氢原子或类似物；R6和R7可以相同或不同，且各自独立地是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1至Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST
  申请人：Miyoshi Shiro

  公开号：US20080015242A1

  公开（公告）日：2008-01-17

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式（I）的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是（C1-C6）烷基或类似物；R5是氢原子或类似物；R6和R7可以相同也可以不同，分别是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1到Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• Indazole compounds
  申请人：Asahi Kasei Pharma Corporation

  公开号：US08008506B2

  公开（公告）日：2011-08-30

  Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have β3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

  提供的化合物由以下式子(A-1)和式子(1)或其盐所代表。式子(A-1)和式子(1)或其盐具有β3肾上腺素受体激动剂活性，因此可用作治疗和预防糖尿病、肥胖症、高脂血症、抑郁症、胆石或胆道高动力性引起的疾病、消化道高活性引起的疾病、间质性膀胱炎、过度活跃的膀胱或尿失禁的治疗和预防剂，或用作伴随泪液减少的疾病的治疗和预防剂。